Twist Bioscience Stock Forecast

Stock Price Forecast

According to 11 analysts polled by S&P Global, Twist Bioscience stock has a consensus rating of "Strong Buy" and an average price target of $74.1. The average 1-year stock price forecast is 25.33% lower than the current stock price, while the lowest is $36 (-63.72%) and the highest is $95 (-4.27%).

Price Target: $74.1 (-25.33%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$36	$74.1	$77.5	$95
Change	-63.72%	-25.33%	-21.91%	-4.27%

Analyst Ratings

The average analyst rating for Twist Bioscience stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	7	7	7	7	8	8
Buy	1	1	1	1	1	2
Hold	2	2	2	2	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	10	10	10	10	10	11

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Subbu Nambi Guggenheim	Guggenheim	Buy Maintains $60 → $107	Buy	Maintains	$60 → $107	+7.82%	Jun 29, 2026
Luke Sergott Barclays	Barclays	Buy Reiterates $65 → $95	Buy	Reiterates	$65 → $95	-4.27%	Jun 24, 2026
Brendan Smith TD Cowen	TD Cowen	Buy Reiterates $68 → $89	Buy	Reiterates	$68 → $89	-10.32%	Jun 15, 2026
Kyle Mikson CFA Canaccord Genuity	Canaccord Genuity	Buy Initiates $90	Buy	Initiates	$90	-9.31%	Jun 15, 2026
David Westenberg Piper Sandler	Piper Sandler	Buy Initiates $85	Buy	Initiates	$85	-14.35%	Jun 11, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

446.41M

from 376.57M

18.55%

from 376.57M

Revenue Next Year

518.23M

from 446.41M

16.09%

from 446.41M

EPS This Year

-0.77

from -2.12

EPS Next Year

-0.76

from -0.77

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Sep 30, 2021	Sep 30, 2022	Sep 30, 2023	Sep 30, 2024	Sep 30, 2025	Sep 30, 2026
Revenue	132.33M	203.57M	245.11M	312.97M	376.57M	446.41M
Revenue Growth	46.87%	53.83%	20.41%	27.69%	20.32%	18.55%
Gross Profit	51.71M	84.24M	89.73M	133.35M	191.00M	233.18M
Gross Margin	39.08%	41.38%	36.61%	42.61%	50.72%	52.23%
Operating Income	-153.26M	-249.02M	-206.90M	-175.90M	-136.26M	-135.86M
Net Income	-152.10M	-217.86M	-204.62M	-208.73M	-77.67M	-128.95M
EPS	-	-	-	-	-2.12	-0.77
Free Cash Flow	-73.09M	-160.52M	-112.43M	-17.42M	-32.63M	-83.80M
No. Analysts	-	-	-	-	-	9

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	447.0M
Avg	446.4M
Low	445.0M

Revenue Growth

Revenue Growth	2026	2027	2028
High	18.7%
Avg	18.5%
Low	18.2%

EPS Forecast

EPS	2026	2027	2028
High	-0.58
Avg	-0.77
Low	-0.96

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-